Sign in
Active, not recruitingNo phase

tRNS Treatment for ADHD Symptoms

Key facts

Who runs it
Innosphere
Where
Boston, Houston, and Rochester, United StatesSee the 4 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
People taking part
146 people, planned
Started
15 Jul 2024
Ended
30 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • tRNS
Record updated
17 February 2026

Who can take part

Age
7 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age between 7-12 years old at the time of enrollment
  • Estimated Full Scale IQ ≥ 85 based on WASI-II (Two-subtests Form) NOTE: Results of an equivalent and validated IQ test that were performed in the previous 12 months from the date of enrollment are acceptable. The Investigator must ensure that no significant head injuries, particularly significant head trauma, occurred in this period from the previous test to the enrollment
  • Score above the standard clinical cut-off score for ADHD symptoms on the ADHD DSM-5 scales
  • Meet criteria for ADHD according to DSM-5, using the "gold standard" procedure as described by the American Academy of Pediatrics, which includes a semi-structured interview of the subject and parent(s)/legal guardian(s)
  • Moderate to severe ADHD as defined as having a minimum score of 12 on either the inattention subscale or the and hyperactivity-impulsivity subscale of the baseline ADHD Rating Scale (ADHD-RS), and a Clinical Global Impression-Severity (CGI-S) score at baseline of greater than 4
  • Parent(s)/legal guardian(s) fluent in English, able to complete ADHD-RS scale and attend all study visits
  • Has not taken any medication with central nervous system effects, including prescription medications for ADHD, within 7 days of enrollment, as determined by the investigator based on the subject's medical history from the parent(s)/legal guardian(s) and, as applicable, medical and pharmacy records

Who cannot take part

  • Impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the Investigator
  • Has a history of any medical or psychiatric disorder, disease, condition, injury, symptoms or circumstance that, in the opinion of the principal investigator, may: (1) reduce the subject's ability to fulfill the study requirements as per protocol; or (2) adversely impact the integrity of the data or the validity of the study results
  • Primary DSM-5 axis-1 disorder other than ADHD, which consists of one or more of severe ODD, bipolar psychosis, major depressive disorder, severe oppositional defiant disorder that would pose adherence challenges by the investigator
  • Known hypersensitivity to Polyamide or Elastomer
  • Any other condition, which would make the participant unsuitable to participate in this study as determined by the Investigator
  • Any suicide risk as assessed with the Columbia-Suicide Severity Rating Scale (Pediatric (≤11 years) Quick Screen)
  • Substance abuse, that, in the opinion of the investigator, may: (1) reduce the participant's ability to fulfill the study requirements as per protocol; or (2) adversely impact the integrity of the data or the validity of the study results
  • If female, began menstruation, based on a self- or parent(s)/legal guardian(s)-report
  • Inability to provide informed consent and assent (participant and parent(s)/legal guardian(s))

Where in United States

Also in 1 other country, 1 site

  • Boston Children's HospitalBoston, United States
  • Baylor College of Medicine Department of Psychiatry & Behavioral SciencesHouston, United States
  • UTHealth HoustonHouston, United States
  • Mayo Clinic Hospital - Methodist CampusRochester, United States

About the trial

What the trial wants to find out

A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.

The 2 groups in the trial

  • Group A: Treatment ArmExisting treatment, for comparison

    The same device placement will be used for sham as in the active arm.

    Treatment: tRNS

  • Group B: Sham-Control ArmSham treatment, for comparison

    The same device placement will be used for sham as in the active arm.

    Treatment: tRNS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 February 2026